Literature DB >> 11163050

The quality of life in patients with pathologic myopia.

T Takashima1, T Yokoyama, S Futagami, K Ohno-Matsui, H Tanaka, T Tokoro, M Mochizuki.   

Abstract

PURPOSE: To evaluate the functional status in daily life and the quality of life (QOL) of pathologic myopia patients.
METHODS: A cross-sectional study was conducted using data of consecutive pathologic myopia patients (n = 200) and control subjects (n = 144). The influence of the disease on the daily life and the QOL of patients were evaluated using a self-rated questionnaire. The questionnaire covered the full range of daily life activity, including daily tasks depending on visual acuity, social and emotional handicaps, and cognition of disease, and the QOL of pathologic myopia patients.
RESULTS: The functional status in daily life and the QOL of patients were reduced compared with control subjects. The influence of pathologic myopia on a patient's daily life was primarily the result of three major factors, handicap, disability, and support. All three factors correlated with the QOL, the degree of handicap having the strongest correlation.
CONCLUSION: The functional status in daily life and the QOL of pathologic myopia patients were reduced; this decline in QOL was attributed to handicap and disability caused by the ocular disease.

Entities:  

Mesh:

Year:  2001        PMID: 11163050     DOI: 10.1016/s0021-5155(00)00305-1

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  10 in total

Review 1.  Myopia.

Authors:  Douglas R Fredrick
Journal:  BMJ       Date:  2002-05-18

Review 2.  Epidemiology of myopia.

Authors:  P J Foster; Y Jiang
Journal:  Eye (Lond)       Date:  2014-01-10       Impact factor: 3.775

Review 3.  Verteporfin : a review of its use in the management of subfoveal choroidal neovascularisation.

Authors:  Susan J Keam; Lesley J Scott; Monique P Curran
Journal:  Drugs       Date:  2003       Impact factor: 9.546

4.  Predictive factors for comorbid psychiatric disorders and their impact on vision-related quality of life in patients with high myopia.

Authors:  Tae Yokoi; Muka Moriyama; Kengo Hayashi; Noriaki Shimada; Makoto Tomita; Naoki Yamamoto; Toru Nishikawa; Kyoko Ohno-Matsui
Journal:  Int Ophthalmol       Date:  2013-06-21       Impact factor: 2.031

5.  Treatment Satisfaction and Well-Being in Patients with Myopic Choroidal Neovascularization Treated with Ranibizumab in the REPAIR Study.

Authors:  Winfried M Amoaku; Richard P Gale; Andrew J Lotery; Geeta Menon; Sobha Sivaprasad; Jennifer Petrillo; Jennifer Quinn
Journal:  PLoS One       Date:  2015-06-03       Impact factor: 3.240

6.  Retinal and Choroidal Thickness in Patients with High Myopia without Maculopathy.

Authors:  Kuddusi Teberik; Murat Kaya
Journal:  Pak J Med Sci       Date:  2017 Nov-Dec       Impact factor: 1.088

7.  Coronavirus disease 2019 outbreak and associated public health measures increase the progression of myopia among children and adolescents: Evidence synthesis.

Authors:  Akarapon Watcharapalakorn; Teera Poyomtip; Patarakorn Tawonkasiwattanakun
Journal:  Ophthalmic Physiol Opt       Date:  2022-03-22       Impact factor: 3.992

8.  APLP2 Regulates Refractive Error and Myopia Development in Mice and Humans.

Authors:  Andrei V Tkatchenko; Tatiana V Tkatchenko; Jeremy A Guggenheim; Virginie J M Verhoeven; Pirro G Hysi; Robert Wojciechowski; Pawan Kumar Singh; Ashok Kumar; Gopal Thinakaran; Cathy Williams
Journal:  PLoS Genet       Date:  2015-08-27       Impact factor: 5.917

9.  Involvement of GABA transporters in atropine-treated myopic retina as revealed by iTRAQ quantitative proteomics.

Authors:  Veluchamy A Barathi; Shyam S Chaurasia; Michael Poidinger; Siew Kwan Koh; Dechao Tian; Candice Ho; P Michael Iuvone; Roger W Beuerman; Lei Zhou
Journal:  J Proteome Res       Date:  2014-10-01       Impact factor: 4.466

Review 10.  A Review of Current Concepts of the Etiology and Treatment of Myopia.

Authors:  Jeffrey Cooper; Andrei V Tkatchenko
Journal:  Eye Contact Lens       Date:  2018-07       Impact factor: 2.018

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.